Morning Briefing
Summaries of health policy coverage from major news organizations
Pfizer Vaccine Highly Effective During Omicron For Kids 5-11, New Data Show
Stat: CDC Data Suggest Pfizer Vaccine Protection Holds Up In Kids 5-11
Does the Pfizer-BioNTech Covid-19 vaccine provide less protection to children aged 5 to 11 than to adolescents 12 to 17? A study from New York state released Monday suggests that’s the case. But new data from 10 states released Tuesday tell a different story. The data, published by the Centers for Disease Control and Prevention, suggest that two doses of the Pfizer vaccine aren’t very protective against infection for either age group in the face of the Omicron variant, but that protection against severe illness appears to be holding up equally in both sets of children. They do not suggest more rapid waning, or more marked waning, among the younger group of children. (Branswell, 3/1)
The Wall Street Journal: Pfizer’s Covid-19 Vaccine Protected Kids During Omicron, CDC Study Finds
The Covid-19 vaccine from Pfizer Inc. and partner BioNTech SE was highly effective at reducing the risk of severe disease in children 17 years and younger during the Omicron surge but didn’t work as well at preventing infection, according to a new government study. The two-dose vaccine reduced the risk of Covid-19 hospitalization in children 5 to 11 years by 74% and by 92% or higher in children 12 to 17, according to the study published Tuesday by the Centers for Disease Control and Prevention. (Hopkins, 3/1)
AP: Pfizer Shots Protect Kids From Severe COVID Even In Omicron
Pfizer’s COVID-19 vaccine gave children 5 and older strong protection against hospitalization and death even during the omicron surge that hit youngsters especially hard, U.S. health officials reported Tuesday. New data from the Centers for Disease Control and Prevention come a day after a study of New York children suggested the vaccine may not be as effective in 5- to 11-year-olds as in older kids -- especially at blocking milder infections. That data raised the question of whether kid-sized doses given to those under 12 might be too low. (Neergaard, 3/1)
